Loading…
Speciality Medicines (BSE 544738)₹155.00+4.06%Pharmaceuticals
In the Mar 2026 quarter (standalone), Speciality Medicines reported sales of ₹44.93 Cr, up 45.2% from Mar 2025, and net profit of ₹8.01 Cr, up 166.1% year on year. For the year to Mar 2026, sales were ₹74.88 Cr and net profit ₹13.01 Cr.
Company filings, standalone accounts; latest reported quarter Mar 2026
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Sales | 30.94 | 44.93 |
| Expenses | 25.95 | 35.92 |
| Operating Profit | 3.99 | 7.99 |
| OPM % | 14.0% | 19.0% |
| Other Income | 0.00 | 1.01 |
| Interest | 0.00 | 0.99 |
| Depreciation | 0.00 | 0.00 |
| Profit before tax | 3.99 | 7.98 |
| Tax % | 36.1% | −1.0% |
| Net Profit | 3.01 | 8.01 |
| EPS (Rs) | 4.17 | 9.32 |
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Sales | 39.89 | 22.97 | 27.93 | 57.88 | 74.88 |
| Expenses | 37.90 | 19.98 | 21.94 | 48.91 | 61.87 |
| Operating Profit | 1.99 | 3.99 | 4.99 | 8.98 | 13.98 |
| OPM % | 6.0% | 15.0% | 19.0% | 16.0% | 18.0% |
| Other Income | 0.00 | 0.00 | 0.00 | 0.00 | 1.01 |
| Interest | 0.00 | 0.00 | 0.99 | 0.99 | 0.99 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 1.99 | 2.99 | 4.99 | 8.97 | 12.96 |
| Tax % | 31.1% | 43.1% | 36.1% | 1.0% | 0.0% |
| Net Profit | 1.01 | 2.01 | 3.01 | 9.01 | 13.01 |
| EPS (Rs) | 70.56 | 4.43 | 5.74 | 13.40 | 14.85 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Equity Capital | 0.22 | 4.01 | 5.01 | 6.02 | 9.03 |
| Reserves | 1.99 | 1.99 | 9.98 | 24.01 | 61.97 |
| Borrowings | 0.99 | 3.98 | 2.99 | 5.00 | 7.00 |
| Other Liabilities | 3.01 | 4.02 | 5.02 | 5.03 | 17.08 |
| Total Liabilities | 6.00 | 13.00 | 23.00 | 40.06 | 95.08 |
| Fixed Assets | 1.99 | 1.99 | 0.99 | 1.99 | 1.99 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 4.01 | 11.01 | 21.01 | 38.07 | 93.09 |
| Inventories | 0.49 | 4.61 | 8.05 | 17.45 | 28.42 |
| Trade receivables | 2.58 | 5.49 | 10.68 | 9.54 | 26.38 |
| Cash & equivalents | 0.09 | 0.27 | 0.26 | 0.84 | 24.56 |
| Total Assets | 6.00 | 13.00 | 23.00 | 40.06 | 95.08 |
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Cash from operating activity | 1.01 | −4.01 | −5.01 | −6.02 | −1.01 |
| Cash from investing activity | −2.01 | 0.00 | 0.00 | −2.01 | −3.01 |
| Cash from financing activity | 1.99 | 3.99 | 4.99 | 7.99 | 27.98 |
| Net cash flow | 0.00 | 0.00 | 0.00 | 0.99 | 23.91 |
| Capex | 2.08 | 0.07 | 0.02 | 0.60 | 0.00 |
| Free cash flow | −1.01 | −4.01 | −4.99 | −6.01 | −0.99 |
| CFO / OP % | 36.0% | −101.0% | −66.0% | −63.0% | −9.0% |
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Debtor days | 23 | 87 | 142 | 60 | 128 |
| Inventory days | 5 | 103 | 161 | 150 | 191 |
| Days payable | 12 | 40 | 48 | 8 | 80 |
| Cash conversion cycle | 16 | 149 | 255 | 202 | 239 |
| Working capital days | −3 | 76 | 185 | 180 | 221 |
| ROCE % | — | 52.0% | 37.9% | 34.0% | 25.0% |
For the Mar 2026 quarter, Speciality Medicines reported sales of ₹44.93 Cr, up 45.2% year on year and net profit of ₹8.01 Cr, up 166.1% year on year. The operating margin was 19.0%.
Speciality Medicines' sales for the year to Mar 2026 were ₹74.88 Cr.
Net profit for the year to Mar 2026 was ₹13.01 Cr. Earnings per share over the same trailing period were ₹14.85.
Speciality Medicines reported borrowings of ₹7 Cr at Mar 2026, against cash and equivalents of ₹24.56 Cr.
Cash from operations was −₹1.01 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹0.99 Cr.